The purpose of this study is to assess an "adaptive" approach to smoking cessation
pharmacotherapy. The protocol is designed to compare adaptive vs. standard approaches to two
common smoking cessation pharmacotherapies - Varenicline (commonly known as Chantix) and the
Nicotine Patch. The investigators hypothesize that participants allocated to adaptive therapy
will show significantly higher biochemically confirmed 30-day continuous abstinence at 12
weeks post-Target Quit Day (TQD).